Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients

AIDS

Volumn 29, Issue 5, 2015, Pages 559-569

  Dickens, Alex M ^a,b   Anthony, Daniel C ^a   Deutsch, Reena ^c   Mielke, Michelle M ^d   Claridge, Timothy D W ^e   Grant, Igor ^c   Franklin, Donald ^c   Rosario, Debra ^c   Marcotte, Thomas ^c   Letendre, Scott ^c   McArthur, Justin C ^b   Haughey, Norman J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

brain energy metabolism; HIV; HIV associated neurocognitive disorders; metabolomics

Indexed keywords

ACETIC ACID; ALANINE; ANTIRETROVIRUS AGENT; CITRIC ACID; CREATINE; CREATININE; GLUCOSE; GLUTAMINE; INOSITOL; LACTIC ACID; PYROGLUTAMIC ACID; BIOLOGICAL MARKER;

ANAEROBIC GLYCOLYSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; VIRUS LOAD; AIDS DEMENTIA COMPLEX; CEREBROSPINAL FLUID; CHEMISTRY; COMPLICATION; ENERGY METABOLISM; GLYCOLYSIS; LONGITUDINAL STUDY; METABOLOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROGNOSIS;

AIDS DEMENTIA COMPLEX; BIOMARKERS; CEREBROSPINAL FLUID; ENERGY METABOLISM; GLYCOLYSIS; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOME; PROGNOSIS;

EID: 84926524046     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000580     Document Type: Article

References (70)

1. McArthur JC, Hoover D, Bacellar H, Miller E, Cohen B, Becker J, et al. Dementia in AIDS patients incidence and risk factors. Neurology 1993; 43:2245-12245.
2. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004; 61:1699.
3. Simioni S, Cavassini M, Annoni J-M, Abraham AR, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
4. Heaton R, Clifford D, Franklin D, Woods S, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. Neurology 2010; 75:2087-2096.
5. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
6. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010; 67:699-714.
7. Canestri A, Lescure F-X, Jaureguiberry S, Moulignier A, Amiel C, Marcelin A, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
8. Kosmiski LA, Ringham BM, Grunwald GK, Bessesen DH. Dualenergy X-ray absorptiometry modeling to explain the increased resting energy expenditure associated with the HIV lipoatrophy syndrome. Am J Clin Nutr 2009; 90:1525-1531.
9. Savage DB, Murgatroyd PR, Chatterjee VK, O'Rahilly S. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J Clin Endocrinol Metab 2005; 90:1446-1452.
10. Melchior J-C, Salmon D, Rigaud D, Leport C, Bouvet E, Detruchis P, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991; 53:437-441.
11. Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, Davila-Roman VG, et al. Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a crosssectional analysis. Cardiovasc Diabetol 2011; 10:111.
12. Reeds DN, Stuart CA, Perez O, Klein S. Adipose tissue, hepatic, and skeletal muscle insulin sensitivity in extremely obese subjects with acanthosis nigricans. Metabolism 2006; 55:1658-1663.
13. Chang E, Sekhar R, Patel S, Balasubramanyam A. Dysregulated energy expenditure in hiv-infected patients: a mechanistic review. Clin Infect Dis 2007; 44:1509-1517.
14. Mohamed MA, Barker PB, Skolasky RL, Selnes OA, Moxley RT, Pomper MG, et al. Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging 2010; 28:1251-1257.
15. Marcotte T, Deutsch R, Michael B, Franklin D, Cookson D, Bharti A, et al. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol 2013; 8:1123-1135.
16. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia 1967; 5:135-140.
17. Reitan RM, Davison LA. Clinical Neuropsychology: current status and applications. Oxford: VH Winston & Sons; 1974.
18. Benedict RH, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 1998; 12:43-55.
19. Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead-Reitan Battery: demographic corrections, research findings, and clinical applications. Florida: Psychological Assessment Resources Odessa; 1991.
20. Wechsler D. WAIS-III: Wechsler adult intelligence scale. San Antonio: Psychological Corporation; 1997.
21. Diehr MC, Heaton RK, Miller W, Grant I. The Paced Auditory Serial Addition Task (PASAT): norms for age, education, and ethnicity. Assessment 1998; 5:375-387.
22. Kløve H. Grooved pegboard. Indiana: Lafayette Instruments; 1963.
23. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB3.0: the Human Metabolome database in 2013. Nucleic Acids Res 2013; 41:D801-D807.
24. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009; 37:D603.
25. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, et al. HMDB: the Human Metabolome database. Nucleic Acids Res 2007; 35:D521-D526.
26. Waterman C, Currie R, Cottrell L, Dow J, Wright J, Waterfield C, et al. An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics 2010; 11:9.
27. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees.Wadsworth International Group; 1984.
28. Erbsloh F, Bernsmeier A, Hillesheim H. The glucose consumption of the brain & its dependence on the liver. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 1958; 196:611-626.
29. Deelchand DK, Shestov AA, Koski DM, Uʇurbil K, Henry P-G. Acetate transport and utilization in the rat brain. J Neurochem 2009; 109:46-54.
30. Muir D, Berl S, Clarke DD. Acetate and fluoroacetate as possible markers for glial metabolism in vivo. Brain Res 1986; 380:336-340.
31. Blüml S, Panigrahy A, Laskov M, Dhall G, Krieger MD, Nelson MD, et al. Elevated citrate in pediatric astrocytomas with malignant progression. Neurooncology 2011; 13:1107-1117.
32. Blum H, Balschi J, Johnson R. Coupled in vivo activity of creatine phosphokinase and the membrane-bound (NaR, KR)-ATPase in the resting and stimulated electric organ of the electric fish Narcine brasiliensis. J Biol Chem 1991; 266:10254-10259.
33. Saks V, Rosenshtraukh L, Smirnov V, Chazov E. Role of creatine phosphokinase in cellular function and metabolism. Can J Physiol Pharmacol 1978; 56:691-706.
34. Schuenke K, Gelman BB. Human microglial cell isolation from adult autopsy brain: brain pH, regional variation, and infection with human immunodeficiency virus type 1. J Neurovirol 2003; 9:346-357.
35. Kure K, Lyman WD, Weidenheim KM, Dickson DW. Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol 1990; 136:1085.
36. Jordan CA, Watkins BA, Kufta C, Dubois-Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991; 65:736-742.
37. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4:543-555.
38. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus: associated dementia. Ann Neurol 2009; 66:253-258.
39. Dewhurst S, Bresser J, Stevenson M, Sakai K, Evinger-Hodges MJ, Volsky DJ. Susceptibility of human glial cells to infection with human immunodeficiency virus (HIV). FEBS Lett 1987; 213:138-143.
40. Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 1995; 9:1001-1008.
41. Fiala M, Rhodes RH, Shapshak P, Nagano I, Martinez-maza O, Diagne A, et al. Regulation of HIV-1 infection in astrocytes: expression of Nef, TNF-a and IL-6 is enhanced in coculture of astrocytes with macrophages. J Neurovirol 1996; 2:158-166.
42. Janabi N, Di StefanoM, Wallon C, HeryC, Chiodi F, Tardieu M. Induction of human immunodeficiency virus type 1 replication in human glial cells after proinflammatory cytokines stimulation: effect of IFNg, IL1b, and TNFa on differentiation and chemokine production in glial cells. Glia 1998; 23:304-315.
43. Saito Y, Sharer L, Epstein L, Michaels J, Mintz M, Louder M, et al. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 1994; 44:474-1474.
44. Nath A, Hartloper V, Furer M, Fowke KR. Infection of human fetal astrocytes with HIV-1: viral tropism and the role of cell to cell contact in viral transmission. J Neuropathol Exp Neurol 1995; 54:320-330.
45. McCarthy M, He J, Wood C. HIV-1 strain-associated variability in infection of primary neuroglia. J Neurovirol 1998; 4:80-89.
46. Starling I, Wright A, Arbuthnott G, Harkiss G. Acute in vivo neurotoxicity of peptides from Maedi Visna virus transactivating protein Tat. Brain Res 1999; 830:285-291.
47. Gjedde A, Marrett S. Glycolysis in neurons, not astrocytes, delays oxidative metabolism of human visual cortex during sustained checkerboard stimulation in vivo. J Cereb Blood Flow Metab 2001; 21:1384-1392.
48. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747-1751.
49. Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med 2010; 11:642-649.
50. Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B. In vivo evidence for lactate as a neuronal energy source. J Neurosci 2011; 31:7477-7485.
51. Pellerin L, Magistretti PJ. Sweet sixteen for ANLS. J Cereb Blood Flow Metab 2011; 32:1152-1166.
52. Patel AB, Lai JC, Chowdhury GM, Hyder F, Rothman DL, Shulman RG, et al. Direct evidence for activity-dependent glucose phosphorylation in neurons with implications for the astrocyte-to-neuron lactate shuttle. Proc Natl Acad Sci 2014; 111:5385-5390.
53. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci 1994; 91:10625-10629.
54. Bittar PG, Charnay Y, Pellerin L, Bouras C, Magistretti PJ. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J Cereb Blood Flow Metab 1996; 16:1079-1089.
55. Pellerin L, Magistretti P. Excitatory amino acids stimulate aerobic glycolysis in astrocytes via an activation of the NaR/KR ATPase. Dev Neurosci 1996; 18:336-342.
56. Dienel GA. Brain lactate metabolism: the discoveries and the controversies. J Cereb Blood Flow Metab 2011; 32:1107-1138.
57. Yang J, Ruchti E, Petit J-M, Jourdain P, Grenningloh G, Allaman I, et al. Lactate promotes plasticity gene expression by potentiating NMDA signaling in neurons. Proc Natl Acad Sci 2014; 111:12228-12233.
58. Tang F, Lane S, Korsak A, Paton J, Gourine A, Kasparov S, et al. Lactate-mediated glia-neuronal signalling in the mammalian brain. Nat Commun 2014; 5:3284.
59. Fernandes S, Edwards T, Ng K, Robinson S. HIV-1 protein gp120 rapidly impairsmemory in chicks by interrupting the glutamate-glutamine cycle. Neurobiol Learn Mem 2007; 87:1-8.
60. Vartak-Sharma N, Gelman BB, Joshi C, Borgmann K, Ghorpade A. Astrocyte elevated gene-1 is a novel modulator of HIV-1-associated neuroinflammation via regulation of nuclear factor-kB signaling and excitatory amino acid transporter-2 repression. J Biol Chem 2014; 289:19599-19612.
61. Visalli V, Muscoli C, Sacco I, Sculco F, Palma E, Costa N, et al. N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction. BMC Neurosci 2007; 8:106.
62. Cohen RA, Harezlak J, Gongvatana A, Buchthal S, Schifitto G, Clark U, et al. Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol 2010; 16:435-444.
63. Cysique LA, Moffat K, Moore DM, Lane TA, Davies NW, Carr A, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a 1H MRS study. PLoS One 2013; 8:e61738.
64. Chang L, Lee P, Yiannoutsos C, Ernst T, Marra C, Richards T, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004; 23:1336-1347.
65. Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 2013; 13:203.
66. Rottenberg DA, Sidtis JJ, Strother SC, Schaper KA, Anderson JR, Nelson MJ, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996; 37:1133-1141.
67. Andersen ÅB, Law I, Krabbe KS, Bruunsgaard H, Ostrowski SR, Ullum H, et al. Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation 2010; 7:13.
68. Towgood KJ, Pitkanen M, Kulasegaram R, Fradera A, Soni S, Sibtain N, et al. Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. Hum Brain Mapp 2013; 34:2484-2493.
69. Ernst T, Jiang CS, Nakama H, Buchthal S, Chang L. Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging 2010; 32:1045-1053.
70. Gongvatana A, Harezlak J, Buchthal S, Daar E, Schifitto G, Campbell T, et al. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol 2013; 19:209-218.